The purpose of this study is to evaluate accuracy of magnetic resonance imaging (MRI) for local staging of bladder cancer for four clinical scenarios (T-stage thresholds) considered against current standards for clinical staging and secondarily to identify sources for variability in accuracy. Systematic review of patients with bladder cancer undergoing T-staging MRI to evaluate the diagnostic accuracy using bivariate random-effects meta-analysis. Sub-group analysis was done to explore variability; risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. The search identified 30 studies (5156 patients). Pooled accuracy at multiple T-stage thresholds: ≤T1 vs ≥T2 = sensitivity 87% (95% confidence interval [CI] 82-91), specificity 79% (95% CI 72-85); T-any vs T0 = sensitivity 65% (95% CI 23-92), specificity 90% (95% CI 83-94); ≤T2 vs ≥T3 = sensitivity 83% (95% CI 75-88), specificity 87% (95% CI 78-93); and <T4b vs pT4b = sensitivity 85% (95% CI 63-95), specificity 98% (95% CI 95-99). For ≤T1 vs ≥T2, accuracy was higher in studies at low risk of bias. No variability in accuracy was identified for: field strength, transurethral resection of bladder tumour status, publication date, index test parameters. For ≤T1 vs ≥T2, accuracy was higher than reported for clinical staging. For T-any vs T0 accuracy was lower than clinical staging. For ≤T2 vs ≥T3, sensitivity was slightly lower than clinical staging but specificity was considerably higher. For <T4b vs pT4b sensitivity exceeded the estimated accuracy for clinical staging. Limitations: two scenarios had few studies (T-any vs T0; <T4b vs pT4b) and several studies were at high risk of bias. MRI staging for ≤T1 vs ≥T2, ≤T2 vs ≥T3, and <T4b vs pT4b should be considered as potentially superior to the current standard for clinical staging. MRI accuracy for T-any vs T0 may not be superior to clinical staging. However, cautious interpretation is warranted related to risk of bias and sample size; validation in trials comparing clinical staging strategies vs MRI is warranted.
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Introduction
Bladder cancer is common;~430 000 new cases are diagnosed annually worldwide [1] . Treatment recommendations from practice guidelines are driven by the extent of primary tumour (i.e. clinical T-stage); this is determined by a combination of clinical and imaging parameters [2, 3] . Both the European Society of Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines recommend pelvic CT or MRI for local staging with the caveat that neither test is often able to differentiate T2 from higher stage tumours [2, 3] . Although direct comparisons of CT vs MRI for local staging of bladder cancer have not been done, based on our knowledge of optimal local staging for other pelvic tumours. such as rectum and prostate, it is reasonable to infer that MRI provides superior accuracy to CT [4] [5] [6] .
The 'clinical' tests that are relied upon for local staging (cystoscopy, examination under anaesthesia and transurethral resection of bladder tumour [TURBT]) may also be suboptimal. The most extensive evaluation of clinical staging identified that 40% of patients with clinical non-muscle invasive bladder cancer (NMIBC) were upstaged at cystectomy, whilst 36% with clinical organ-confined disease had locally advanced disease at cystectomy [7] . These modest clinical staging outcomes, and the fact that MRI has less morbidity than alternatives, such as TURBT [8] , indicate that evaluating the accuracy of MRI as an alternative test to clinical staging is warranted.
Local staging of bladder cancer is based primarily on anatomical T2-weighted (T2W) sequences [9, 10] . The use of quantitative features such as the apparent diffusion coefficient (ADC) value of tumours (obtained from diffusion-weighted imaging [DWI]), and dynamic contrast enhancement (DCE) have shown promise for local staging [11, 12] . These evaluations of MRI are limited by small sample sizes and variable techniques. Previous meta-analyses on MRI for staging of bladder cancer are limited by restricted focus on the index test (e.g., DWI only [13] ) or focus on only one threshold of disease (e.g., ≤T1 vs ≥T2 [9, 14] ).
The purpose of the present study was to evaluate accuracy of MRI for local staging of bladder cancer for four clinical scenarios (T-stage thresholds) considered against current standards for clinical staging. The secondary objective was to identify sources for variability in accuracy.
Methods
Conducted and reported by best-practices for diagnostic accuracy of systematic reviews [15] [16] [17] . Reporting was done as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for diagnostic test accuracy (DTA) [16, 18] . Protocol registered (PROSPERO: CRD42017054883). Clinical-scenarios and meta-analysis methods based on multidisciplinary group with expertise in diagnostic accuracy meta-analysis, and multi-disciplinary care of patients with bladder cancer (medical-radiation oncology, urology, pathology, radiology).
Clinical Scenarios
The following scenarios relevant to T-stage thresholds were evaluated:
1 Question 1 (Q1): Can MRI differentiate ≤T1 from ≥T2 before and/or after initial TURBT identifying ≤T1 tumour (to replace re-resection prior to intravesical therapy; to guide use of neoadjuvant chemotherapy)? 2 Question 2 (Q2): Can MRI determine T-any vs T0 before and/or after initial TURBT? Pre-TURBT includes scenarios of post-radiation monotherapy, post-chemotherapy or postchemoradiation. 3 Question 3 (Q3): Can MRI differentiate ≤T2 vs ≥T3 before and/or after initial TURBT or re-resection (this information can be used to help guide patients on the benefit/harm balance of neoadjuvant chemotherapy)? 4 Question 4 (Q4): Can MRI determine <T4b vs pT4b
(to determine feasibility of resection vs palliative radiation)?
Comparator (Clinical Staging)
As diagnostic accuracy is not a property with absolute value in and of itself, it is optimal to evaluate it in relation to the alternative test, in this case clinical staging [15, 19] . Accuracy estimates for Q1 and Q3 will be compared to those from the clinical staging cohort referenced by practice guidelines (no clinical staging systematic review or other cohorts were identified). Clinical staging in this cohort included: TURBT, bimanual examination before and after TUR under general anaesthesia, chest radiography and upper urinary tract imaging (abdomen CT or IVU) [7] . Based on this cohort of >700 patients, clinical staging for ≤T1 vs ≥T2 has sensitivity = 64% and specificity = 77%; for ≤T2 vs ≥T3 sensitivity = 97% and specificity = 22% [7] . For Q2 and Q4 (where no such external reference is available), our study group identified reference parameters based on consensus opinion: Q2: minimum accuracy for Q2 for clinical utility was specificity >95% (specificity >sensitivity is valued in this scenario). Q4: Minimum accuracy for clinical utility was sensitivity >80% (sensitivity >specificity is valued in this scenario).
Search Strategy
Searches of Medline, Embase, Cochrane Central Register of Controlled Trials, a database of abstracts of reviews of effects, and the Cochrane Database of Systematic Reviews were performed with the assistance of a librarian [20] . No language restrictions were applied. Screening and inclusion was done independently by two authors (N.G., M.D.F.M.). Titles and abstracts were screened for relevance, full texts retrieved and inclusion criteria applied. Reference lists of included studies were checked. Conference proceedings from the last 3 years and clinical trials registries were queried for relevant unpublished studies by one author (N.G.). T-staging definitions were according to the eighth edition of the American Joint Cancer Committee (AJCC) manual [10] . For Q1: true positive = positive index test (invasion of the detrusor muscle by tumour on MRI) and diagnosis of ≥T2 disease by the reference standard; true negative = negative test (detrusor muscle not invaded by tumour on MRI) and diagnosis of ≤T1 disease confirmed by reference standard; false positive = positive test not confirmed by reference standard; false negative = negative test disproven by reference standard. Similar definitions were applied at different T-stage thresholds for Q2-4. Non-diagnostic tests were excluded from the analysis on the assumption that they occur randomly [21] . Cases to which no reference standard was applied, or with non-urothelial histology, were excluded when possible. For primary studies that provide independent data sets for multiple readers, average data were used for inclusion in meta-analysis [22] .
Inclusion Criteria
Customised Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 (a tool for quality assessment of diagnostic accuracy studies in systematic reviews) tool (Appendix S1) was applied [23] . Publication bias was not assessed as there is no agreed upon method for test accuracy in meta-analysis [15, 17] .
Data Analysis
For each study, 2 9 2 contingency table data were summarised in forest plots of sensitivity-specificity. Sensitivity, specificity (with sample size and prevalence) values were used to calculate 2 9 2 data if it was not provided. Sensitivity-specificity were pooled using a bivariate random-effects model [when >1 accuracy estimate for various index test parameters (e.g. multiple ADC thresholds) were reported, the data with the highest Youden's index was used for meta-analysis] [24] . For Q1-4, subgroup analyses to identify sources of variability in accuracy were performed for subgroups with five or more studies. [26, 27] .
Results
Search Figure 1 shows the search, screening and inclusion process. Appendix S2 lists search details (search updated 20 January 2017), Appendix S3 lists excluded studies at full-text screen, Appendix S4 lists included study references. [10] ; patients were re-classified to the eighth edition definitions for 2 9 2 tables.
Characteristics of Included Studies

Data Analysis
Appendices S10a, S11, S12a, S13 provide forest plots of sensitivity-specificity for Q1-4. Table 3 lists pooled sensitivity and specificity values for Q1-4. 
Discussion
The present systematic review provides diagnostic accuracy data for four pertinent clinical questions regarding MRI for T-staging of urothelial carcinoma of the bladder. The findings are summarised as follows: Q1: Can MRI differentiate ≤T1 from ≥T2 before and/or after initial TURBT identifying ≤T1 tumour (to replace re-resection prior to intravesical therapy; to guide use of neoadjuvant chemotherapy)? Sensitivity was considerably higher than, and specificity comparable to those for clinical staging [7] . These results based on 25 studies (>3000 patients) indicate that MRI may warrant consideration as a replacement test for re-resection. Importantly, risk of bias is a source of variability; this may be driven by differential verification bias from application of different reference standard (TURBT vs cystectomy) to patients. Of course, unidentified variability should be considered; however, the strength of evidence for clinical staging is likely comparable.
Q2: Can MRI determine T-any vs T0 before and/or after initial TURBT? Specificity did not meet the pre-specified threshold (specificity >95%) to suggest that MRI can be used to determine T-any vs T0 before and/or after initial TURBT. The low number of included studies did not allow for subgroup analyses and half of the included studies were at high risk of bias.
Q3: Can MRI differentiate ≤T2 vs ≥T3 before and/or after initial TURBT or re-resection (this information can be used to help guide patients on the benefit/harm balance of neoadjuvant chemotherapy)? Sensitivity was lower than that for clinical staging (83% vs 97%); however, specificity was considerably higher (87% vs 22%). These results based on 18 studies (>1200 patients) suggest the overall accuracy for MRI is higher than for clinical staging, and might be considered the optimal discriminator for decisions about use of neoadjuvant chemotherapy. Of course, risk of bias and unidentified variability should be considered; however, the strength of evidence for clinical staging is likely comparable.
Q4: Can MRI determine <T4b vs pT4b (to determine feasibility of resection vs palliative radiation)? Sensitivity exceeded the pre-specified threshold (sensitivity >80%) suggesting that MRI could be used to determine feasibility of resection. However, conclusions should be guarded in light of the relatively small number of included studies, high risk of bias in two of the five studies, and lack of subgroup analysis to identify sources of variability.
The accuracy of MRI for local staging of bladder shows promise when compared to the alternative test (clinical staging). These findings may warrant consideration in clinical practice guidelines regarding an expanded role for MRI in informing treatment. MRI may be a viable replacement test for re-resection in a cT1 patient prior to intravesical therapy or cystectomy given the accuracy estimates identified, and the likely lower associated complications of MRI compared with TURBT [8] . Alternatively, MRI could be used in conjunction with the current standard of care in a manner to inform probability of T-stage (using Bayesian probability models). The strength of evidence used for the comparator of clinical staging (which is cited to support this practice in the guidelines) is not strong; major concerns include the relatively small sample, single centre, heterogeneous definition of clinical staging, and differential application of reference standard. As such, it would be optimal to have large multicentre trials comparing clinical staging strategies (with and without MRI) in a prospective cohort to confirm these findings. An important future related research question is whether MRI is a good predictor of treatment response to chemotherapy (to determine candidates for cystectomy). Additional factors to investigate that might impact accuracy of MRI include NMIBC-pT1 high-grade tumours, tumour location, presence of carcinoma in situ, and use of BCG therapy.
Additional limitations include variability in clinical presentation of patients from included studies (e.g. some pre-and some post-TURBT); this many limit generalisability to specific cohorts. Although TURBT (pre vs post) subgroup analysis did not identify differences in accuracy, such an evaluation was only possible for Q1. There was high risk of bias in at least one domain for a substantial portion of studies for Q1-4; risk of bias was a contributor to variability for Q1, but not Q3 and could not be evaluated for Q2 and Q4. Sources for variability in accuracy (such as slice thickness, patient, and treatment factors) could not be evaluated due to limited data/ lack of clear reporting. In addition, the accuracy data used for comparison to clinical staging (Q1 and Q3) was based on a single cohort study; indirect comparisons between difference patient groups are known to be at risk of bias [28] . Furthermore, the reference thresholds used for Q2 and Q4 based on local expert consensus could be criticised as being somewhat arbitrary; we consider this an indication that more research on both MRI and clinical staging accuracy for Q2 and Q4 are badly needed.
Conclusion
MRI staging for Q1 (≤T1 vs ≥T2), Q3 (≤T2 vs ≥T3) and Q4 (<T4b vs pT4b) should be considered potentially superior to clinical staging when considering treatment options for bladder cancer. MRI accuracy for Q4 (T-any vs T0) may not be superior to clinical staging.
However, the conclusions regarding Q2 (T-any vs T0) and Q4 (<T4b vs pT4b) should be guarded, as accuracy estimates were based on a small number of included studies. Furthermore, comparisons to clinical staging are indirect, and concerns regarding high risk of bias in included studies are 
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